DexCom (DXCM) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $90.70 -0.11%
Financial Fact:
Interest expense: -200K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Interest expense: -200K
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
DexCom (NASDAQ: DXCM) reported Q4 EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $815.2 million versus the consensus estimate of $809.35 million.
GUIDANCE:
DexCom sees Q1 2023 revenue of $3.35-3.49 billion, versus the consensus of $3.47 billion.
For earnings history and earnings-related data on DexCom (DXCM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
